KPT-8602 has only been investigated in preclinical AML studies; based on patient-derived xenograft models, it was concluded that this agent was active against both AML blasts as well as leukemia-initiating cells and had minimal toxicity to xenografted human CD34+ cells. Here, CD34 is linked to acute myeloid leukemia.